171 related articles for article (PubMed ID: 37872324)
1. IRDiRC Drug Repurposing Guidebook: making better use of existing drugs to tackle rare diseases.
Hechtelt Jonker A; Day S; Gabaldo M; Stone H; de Kort M; O'Connor DJ; Pasmooij AMG
Nat Rev Drug Discov; 2023 Dec; 22(12):937-938. PubMed ID: 37872324
[No Abstract] [Full Text] [Related]
2. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.
Southall NT; Natarajan M; Lau LPL; Jonker AH; Deprez B; Guilliams T; Hunter L; Rademaker CM; Hivert V; Ardigò D;
Orphanet J Rare Dis; 2019 Oct; 14(1):225. PubMed ID: 31615551
[TBL] [Abstract][Full Text] [Related]
3. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.
Hechtelt Jonker A; Hivert V; Gabaldo M; Batista L; O'Connor D; Aartsma-Rus A; Day S; Sakushima K; Ardigo D
Nat Rev Drug Discov; 2020 Aug; 19(8):495-496. PubMed ID: 32313251
[No Abstract] [Full Text] [Related]
4. Drug repurposing in rare diseases: Myths and reality.
Fetro C; Scherman D
Therapie; 2020 Apr; 75(2):157-160. PubMed ID: 32241561
[TBL] [Abstract][Full Text] [Related]
5. Drug Repurposing for Rare Diseases.
Roessler HI; Knoers NVAM; van Haelst MM; van Haaften G
Trends Pharmacol Sci; 2021 Apr; 42(4):255-267. PubMed ID: 33563480
[TBL] [Abstract][Full Text] [Related]
6. Drug repositioning for rare diseases: Knowledge-based success stories.
Scherman D; Fetro C
Therapie; 2020 Apr; 75(2):161-167. PubMed ID: 32164975
[TBL] [Abstract][Full Text] [Related]
7. Drug repurposing for rare diseases.
Israr J; Alam S; Kumar A
Prog Mol Biol Transl Sci; 2024; 207():231-247. PubMed ID: 38942540
[TBL] [Abstract][Full Text] [Related]
8. Drug repositioning trends in rare and intractable diseases.
Sakate R; Kimura T
Drug Discov Today; 2022 Jul; 27(7):1789-1795. PubMed ID: 35104621
[TBL] [Abstract][Full Text] [Related]
9. eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs.
Brylinski M; Naderi M; Govindaraj RG; Lemoine J
J Mol Biol; 2018 Jul; 430(15):2266-2273. PubMed ID: 29237557
[TBL] [Abstract][Full Text] [Related]
10. Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies.
Jain P; Jain SK; Jain M
Curr Mol Med; 2021; 21(2):111-132. PubMed ID: 32560606
[TBL] [Abstract][Full Text] [Related]
11. A Literature-Based Knowledge Graph Embedding Method for Identifying Drug Repurposing Opportunities in Rare Diseases.
Sosa DN; Derry A; Guo M; Wei E; Brinton C; Altman RB
Pac Symp Biocomput; 2020; 25():463-474. PubMed ID: 31797619
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutic Uses for Existing Drugs.
Austin BA; Gadhia AD
Adv Exp Med Biol; 2017; 1031():233-247. PubMed ID: 29214576
[TBL] [Abstract][Full Text] [Related]
13. In silico repositioning of approved drugs for rare and neglected diseases.
Ekins S; Williams AJ; Krasowski MD; Freundlich JS
Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
[TBL] [Abstract][Full Text] [Related]
14. RDKG-115: Assisting drug repurposing and discovery for rare diseases by trimodal knowledge graph embedding.
Zhu C; Xia X; Li N; Zhong F; Yang Z; Liu L
Comput Biol Med; 2023 Sep; 164():107262. PubMed ID: 37481946
[TBL] [Abstract][Full Text] [Related]
15. Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases.
Del Álamo M; Bührer C; Fisher D; Griese M; Lingor P; Palladini G; Sireau N; Hivert V; Sangiorgi L; Guillot F; Halftermeyer J; Soucková L; Nosková K; Demlová R
Trials; 2022 Sep; 23(1):783. PubMed ID: 36109818
[TBL] [Abstract][Full Text] [Related]
16. Translational and clinical pharmacology considerations in drug repurposing for X-linked adrenoleukodystrophy-A rare peroxisomal disorder.
Tieu JH; Sahasrabudhe SA; Orchard PJ; Cloyd JC; Kartha RV
Br J Clin Pharmacol; 2022 Jun; 88(6):2552-2563. PubMed ID: 34558098
[TBL] [Abstract][Full Text] [Related]
17. Drug target gene-based analyses of drug repositionability in rare and intractable diseases.
Sakate R; Kimura T
Sci Rep; 2021 Jun; 11(1):12338. PubMed ID: 34117295
[TBL] [Abstract][Full Text] [Related]
18. A Global Approach to Rare Diseases Research and Orphan Products Development: The International Rare Diseases Research Consortium (IRDiRC).
Cutillo CM; Austin CP; Groft SC
Adv Exp Med Biol; 2017; 1031():349-369. PubMed ID: 29214582
[TBL] [Abstract][Full Text] [Related]
19. Drug repositioning for orphan diseases.
Sardana D; Zhu C; Zhang M; Gudivada RC; Yang L; Jegga AG
Brief Bioinform; 2011 Jul; 12(4):346-56. PubMed ID: 21504985
[TBL] [Abstract][Full Text] [Related]
20. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.
Tambuyzer E; Vandendriessche B; Austin CP; Brooks PJ; Larsson K; Miller Needleman KI; Valentine J; Davies K; Groft SC; Preti R; Oprea TI; Prunotto M
Nat Rev Drug Discov; 2020 Feb; 19(2):93-111. PubMed ID: 31836861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
